Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for potentially treating Parkinson's disease

A Parkinson's disease and drug technology, applied in the field of medical neuropharmacology, can solve the problems of unclear, cumbersome medication, complex raw material formula, etc., and achieve the effect of improving the symptoms of bradykinesia

Inactive Publication Date: 2017-09-29
JIANGNAN UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, some traditional Chinese medicine compositions for the prevention and treatment of PD have been reported, but these compositions generally have complex raw material formulas and require complex treatments such as extraction of raw materials, resulting in cumbersome medication, and which ingredients play a corresponding role is also ambiguous

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for potentially treating Parkinson's disease
  • Drug for potentially treating Parkinson's disease
  • Drug for potentially treating Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Establishment and grouping of animal models

[0028] 20-25g, 8 weeks old, male C57BL / 6 mice were randomly divided into blank group, MPTP model group (MPTP first and then saline), aucubin administration group (MPTP first and peach leaf Coralin), 20 per group. Placed at 23±2°C, the lighting time is 12h / day, and the animals start to be given drugs after one week of acclimatization to the environment. In the MPTP model group, MPTP (30 mg / kg) was injected intraperitoneally once a day for 5 consecutive days, and then physiological saline was injected intraperitoneally once a day for 7 consecutive days. The administration group received MPTP (30mg / kg) intraperitoneal injection once a day for 5 consecutive days, and then intraperitoneal injection of aucubin (50mg / kg) solution once a day for 7 consecutive days. The blank group was given normal saline for 12 consecutive days. Subsequently, the behavior of the mice was evaluated by the climbing rod experiment, and then ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug for potentially treating Parkinson's disease and belongs to the technical field of medical neuropharmacology. The invention finds the potential application of an iridoid glycoside compound aucubin in the drug for clinically treating Parkinson's disease. According to the invention, a Parkinson's disease animal model is established, various research methods, such as, behavioristics, immunology and biochemical criterion, are comprehensively utilized and an experiment proves that the drug can improve the dyskinesia symptom of a Parkinson's disease model rat; the decreasing of the content of corpus striatum dopamine is reduced; the dopaminergic neuron degeneration of the compact part of substantia nigra is reduced; the aucubin material source is abundant and the effect is excellent, so that the drug has a certain development value and prospect in clinical application.

Description

Technical field [0001] The invention relates to a medicine with potential for treating Parkinson's disease, belonging to the technical field of medical neuropharmacology. Background technique [0002] Parkinson’s disease (PD) is the most common degenerative disease of the motor nervous system. The main clinical manifestations are: resting tremor, slow movement, unstable standing and postural reflex disorders. The main lesions in the brain of patients with Parkinson's disease are the substantia nigra and the striatum. The death and decrease in the number of dopaminergic neurons in the dense part of the substantia nigra are the direct causes of the decrease in dopamine projected into the striatum. At present, the pathogenesis of PD is not clear, but it is clearly different from diseases such as oxidative damage caused by diabetes and encephalopathy, and hippocampal neuronal cell apoptosis. [0003] PD is the second largest neurodegenerative disease after Alzheimer’s disease. The inc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P25/16A23L33/10
CPCA23V2002/00A61K31/7048A23L33/10A23V2200/322
Inventor 申延琴朱营利
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com